Emcure Pharmaceuticals: CARE Ratings Reaffirms Credit Ratings
Emcure Pharmaceuticals Ltd · Others (Uncategorized) · 01 Sept 2026, 9:14 pm
Emcure Pharmaceuticals: CARE Ratings Reaffirms Credit Ratings CARE Ratings reaffirmed its credit ratings for Emcure Pharmaceuticals on 01 Sep'26, citing a healthy business profile. Ratings include 'CARE AA; Stable' for long-term facilities (enhanced to ₹785.00 crore) and 'CARE A1+' for short-term facilities (₹52.00 crore). In FY26, revenue grew ~18% YoY to ₹9,322 crore, driven by international markets. The PBILDT margin improved to 20.0% from 18.7% in FY25. Debt protection metrics remain comfortable, with TD/PBILDT at 0.81x, despite total debt rising to ₹1,519 crore.
Original exchange filing (PDF)
More announcements from Emcure Pharmaceuticals Ltd
- Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026 · 15 Nov 2026
- Transcript of Earnings Call - Q2 FY27 held on Tuesday, November 03, 2026 at 4:00 p.m. (IST) · 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026 · 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026 · 06 Nov 2026
- Audio recording of Earnings Call - Q2 FY27 · 04 Nov 2026
- Presentation on Unaudited Financial Results for the quarter ended September 30, 2026 · 03 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026 · 03 Nov 2026
- Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 03 Nov 2026
